Every year, World Toilet Day is observed to raise awareness about the global sanitation crisis and encourage action to solve it. The goal set by the United Nation is to achieve safe toilets for all by 2023, as a part of their Sustainable Development Goals.

The UN also states that 3.5 billion people live without proper sanitation and many children also lose their lives due to poor sanitation and unsafe water. This is why World Toilet Day is observed to raise awareness on this issue.

Theme

This year, the theme for World Toilet Day 2024 is "Toilets - A Place for Peace'. This focuses on the growing threat to sanitation that is caused by conflict, climate change, disaster and neglect. When there is a threat to using toilets, it can lead to many health risks.

Not using toilets for too long may lead to Urinary Tract Infection or UTI. For many who do not have access to clean toilets do not drink enough liquid or hold pee for too long. Doctors suggest that holding in pee for too long can cause bacteria to multiply and lead to UTI. By not drinking enough water, your bladder fails to tell the body to pee often, and can cause the bacteria to spread through the urinary tract, which can lead to infection.

Symptoms of UTI:

• Burning or stinging feeling while urinating
• Pain in pelvis or lower abdomen
• Constant urge to empty the bladder
• Strong or foul smelling urine
• Consistently dark urine
• Blood in urine

Holding in pee for too long can also cause your bladder to stretch, making it difficult or even impossible for the bladder to contract and release pee normally. It can also damage your pelvic floor muscles or could lead to kidney stones.

World Toilet Day History And Significance

To prevent such conditions, it is important that everyone has access to clean and safe toilets. In terms of history, the day was established in 2001, by the World Toilet Organization (WTO), which was founded by Jack Sim. However, it was officially recognised by the UN in 2013. The Government of Singapore worked with WTO to create the first UN resolution called Sanitation for All.

India too promotes safe and hygiene toilet through its Swachh Bharat Yojna.

The U.S. Senate has confirmed Dr. Erica Schwartz as the next Director of the U.S. Centers for Disease Control and Prevention (CDC), making her the public health agency's first permanent leader in nearly a year after months of uncertainty. The Senate approved her nomination in a 51-44 vote on August 5.

President Donald Trump nominated Schwartz in April, calling her "incredibly talented." During her confirmation hearing, she pledged to lead the CDC with transparency and scientific integrity.

She succeeds acting CDC Director Dr. Jay Bhattacharya, who had been leading the agency since February.

"I will lead with transparency, scientific integrity and accountability," Schwartz told senators during her confirmation hearing.

Schwartz, a physician, lawyer and former U.S. Deputy Surgeon General has an extensive background in medicine.

She takes charge of the CDC at a time when it is battling multiple outbreaks, staff shortages and growing scrutiny and uncertainty over its scientific independence.

Why Dr. Erica Schwartz's Appointment Is Key?

The agency has also undergone major workforce reductions while responding to several public health challenges, including a resurgence of measles, foodborne illness outbreaks and international infectious disease threats.

Schwartz's appointment is expected to bring stability to an agency that plays a central role in tracking disease outbreaks, issuing vaccination recommendations, responding to health emergencies and guiding public health policy in the US.

Also read: US Measles Cases Reach 2,371; RFK Jr Takes U-Turn, Urges Families to Vaccinate Kids

Who is Dr. Erica Schwartz?

Schwartz obtained her medical degree from Brown University and also holds a Master of Public Health and a law degree. She served in the U.S. Navy before joining the U.S. Public Health Service, where she later became Deputy Surgeon General during President Trump's first administration.

She has also served as Chief Medical Officer of the U.S. Coast Guard and most recently held leadership positions in the private healthcare sector.

Her confirmation comes as public health experts closely watch how the CDC balances scientific decision-making with increasing political scrutiny.

Many believe her appointment will be critical in rebuilding confidence in one of the world's most influential public health agencies.

Also read: One In Three Hospital Patients With Serious Mould Infections Died, CDC Study Finds

Erica Schwartz Backs Vaccines, Calls for Autism Research

Dr. Erica Schwartz is President Donald Trump's third CDC nominee in less than two years.

Schwartz ha pledged to restore public trust in the CDC through transparency and evidence-based decision-making during her confirmation hearing before the Senate Committee on Health, Education, Labor, and Pensions (HELP).

Throughout her nomination hearing, Schwartz repeatedly expressed support for vaccines, including mRNA COVID-19 vaccines, and strongly endorsed vitamin K injections for newborns to prevent life-threatening bleeding.

Although she also acknowledged that scientific evidence does not support that vaccines cause autism, she argued that more research is needed to better understand the rising cases of autism.

"We owe it to the American people to figure out why one in 30 children now has autism," she said.

Schwartz stated that she did not believe either President Trump or Health Secretary Kennedy would ask her to take actions that would harm public health or violate the law.

Amid rising global infertility rates, a new study has found that an imbalance in the bacteria present in men's semen may reduce a couple's chances of having a baby and increase the risk of pregnancy loss. Researchers also found that the composition of women's gut bacteria may influence fertility outcomes.

The study, published in The Lancet Obstetrics, Gynaecology & Women's Health, found these associations were particularly evident among couples undergoing in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI), as well as those with a history of recurrent pregnancy loss.

Researchers from the University of Copenhagen, Denmark, said the findings point to "imbalances in men's semen and in women's gut bacteria as previously overlooked and potentially treatable risk factors for infertility and recurrent pregnancy loss."

Although the vaginal microbiome has been studied extensively in relation to fertility, the gut and seminal microbiomes have been largely overlooked.

“Incorporation of couple-level microbial assessment might represent a novel approach for targeted therapeutic strategies,” the team said.

Key Findings

The researchers followed 353 women and 191 of their male partners between April 2018 and September 2023. All participants were heterosexual couples undergoing fertility treatment or had experienced recurrent pregnancy loss.

They analyzed bacterial communities in the women's gut and vagina and in the men's semen before tracking pregnancies and birth outcomes. About one in four men had an unhealthy bacterial imbalance, known as dysbiosis, in their semen.

Among couples undergoing IVF or ICSI:

• 57% of couples in which the male partner had semen dysbiosis had a live birth.

• In comparison, 85% of couples without the imbalance went on to have a baby.

• Pregnancy loss was also more common when the male partner had semen dysbiosis, affecting roughly one in five more couples than those without the imbalance.

The researchers also noted that standard semen analysis cannot detect this bacterial imbalance, meaning a man's test results may appear normal even when dysbiosis is present.

Women's Gut Bacteria Also Affected Fertility

The study found that an imbalance in women's gut bacteria was associated with:

• A lower likelihood of becoming pregnant through fertility treatment.

• A longer time to conceive.

However, gut bacterial imbalance was not associated with miscarriage, while an imbalance in vaginal bacteria showed no clear link with either infertility or pregnancy loss.

What the Findings Mean

According to the researchers, assessing the microbiome in both men and women could improve infertility evaluation and help identify previously overlooked, potentially treatable factors affecting fertility.

They added that, if confirmed in larger studies, therapies aimed at restoring healthy bacterial balance in semen and the gut could improve fertility outcomes and reduce recurrent pregnancy loss.

What Is Infertility?

Infertility is a disease of the male or female reproductive system, defined as the inability to achieve pregnancy after 12 months or more of regular, unprotected sexual intercourse.

According to the World Health Organization (WHO), one in six people globally experience infertility during their lifetime. The condition can cause significant emotional distress, social stigma and financial hardship, with far-reaching effects on mental and psychosocial well-being.

An artificial intelligence (AI)-powered blood test has accurately detected liver cancer in patients from two geographically and biologically distinct populations.

It is being considered a breakthrough that can help researchers develop accessible and effective screening for people at high risk of the disease.

About The Study

The study by researchers from Johns Hopkins University, validated an AI-based blood test in 377 participants from Guatemala and Romania, two populations with different genetic backgrounds and major causes of liver disease.

The findings suggest the technology may be effective across diverse populations. It marks an important step in deploying AI in real-world clinical use.

The test is based on DELFI (DNA Evaluation of Fragments for Early Interception), an AI platform that analyses patterns in cell-free DNA fragments circulating in the bloodstream.

Rather than searching for a single mutation, the algorithm detects subtle changes in how DNA is fragmented, which is a sign of cancer.

Also read: Love Diet Coke? A Major New Study Has Some Concerning News For Your Brain

Better Than Conventional Blood Test

Researchers found that when the DELFI blood test was combined with the commonly used liver cancer biomarker alpha-fetoprotein (AFP), along with a patient's age and sex, it detected 89% of liver cancers overall and 79% of early-stage cancers.

This was significantly better and effective than AFP testing alone, which has limited sensitivity for detecting tumours at an early stage.

The study also provided new insights into why the test performs well, showing that DNA fragmentation patterns carry biological signals linked with liver cancer across different patients from different backgrounds.

According to the researchers, this strengthens confidence that the AI technology could be applied beyond a single country or healthcare setting and can be used to improve liver cancer detection systems.

Also read: Bone Marrow Transplant: The Quiet Revolution Transforming India's Fight Against Blood Cancers

How Does The AI Test Work?

Healthy and cancerous cells release tiny fragments of DNA into the bloodstream. The DELFI platform uses AI to examine the size, distribution, and genomic patterns of these fragments.

Instead of looking for a specific mutation, it recognises fragmentation signs that indicate the presence of liver cancer, making it possible to identify the disease using just a simple blood sample.

While the findings are promising, the researchers emphasised that the test is not yet ready for routine clinical use.

Larger human clinical studies will be needed before it can become part of standard liver cancer screening programmes.

If future trials confirm these results, AI-powered blood tests could become a valuable addition to current cancer detection processes, helping doctors detect liver cancer earlier and improving outcomes for people at highest risk.

Also read: WHO Cancer Agency Flags 3 Common Medicines As Carcinogenic: What It Means For Millions Of Patients

Who Is At Risk?

Hepatocellular carcinoma (HCC), the most common type of liver cancer, is often diagnosed only after symptoms develop, reducing the chances of successful treatment.

People living with cirrhosis, chronic hepatitis B or hepatitis C infection, and metabolic dysfunction-associated steatotic liver disease (MASLD) are at particularly high risk of contracting this disease.

The existing screening methods, including ultrasound and AFP testing, can miss early cancers, while access to imaging is limited in many parts of the world.

A blood-based test that performs consistently across diverse populations could help improve screening and identify cancers when they are still treatable.